Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE-4: V116 Lot Consistency Study in Adults 18-49
NCT05464420Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) at 5 days, Percentage of Participants With Solicited Systemic Adverse Events (AEs) at 5 days and 2 more. Started Aug 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05464420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464420.